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ABSTRACT: Telomerase represents an attractive target in oncology as it is expressed in cancer but not in normal tissues. The
oligonucleotide inhibitors of telomerase represent a promising anticancer strategy, although poor cellular uptake can restrict their
efficacy. In this study, gold nanoparticles (AuNPs) were used to enhance oligonucleotide uptake. “match” oligonucleotides
complementary to the telomerase RNA template subunit (hTR) and “scramble” (control) oligonucleotides were conjugated to
diethylenetriamine pentaacetate (DTPA) for 111In-labeling. AuNPs (15.5 nm) were decorated with a monofunctional layer of
oligonucleotides (ON−AuNP) or a multifunctional layer of oligonucleotides, PEG(polethylene glycol)800-SH (to reduce AuNP
aggregation) and the cell-penetrating peptide Tat (ON−AuNP−Tat). Match−AuNP enhanced the cellular uptake of radiolabeled
oligonucleotides while retaining the ability to inhibit telomerase activity. The addition of Tat to AuNPs increased nuclear
localization. 111In−Match−AuNP−Tat induced DNA double-strand breaks and caused a dose-dependent reduction in clonogenic
survival of telomerase-positive cells but not telomerase-negative cells. hTR inhibition has been reported to sensitize cancer cells to
ionizing radiation, and 111In−Match−AuNP−Tat therefore holds promise as a vector for delivery of radionuclides into cancer cells
while simultaneously sensitizing them to the effects of the emitted radiation.
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■ INTRODUCTION
Telomerase is a ribonucleoprotein with a key role in the
replicative immortality of cancer. Human telomerase is
composed of a telomerase RNA subunit (hTR), which
contains the internal template for the synthesis of telomeric
hexanucleotide DNA repeats, and an enzymatic component,
telomerase reverse transcriptase (hTERT), which catalyzes the
addition of nucleotides at telomere ends. In addition, a number
of accessory proteins (dyskerin, NHP2, NOP10, and GAR1)
are associated with telomerase.1,2 The holoenzyme catalyzes de
novo addition of TTAGGG nucleotide telomeric repeats to
chromosome ends. Telomeres erode in somatic cells during
each cell division as a result of the inability of the DNA
synthesis machinery to perform complete replication (the “end
replication problem”).3 Telomere shortening limits the number
of possible cell divisions since critically short telomeres induce
senescence or apoptosis.4,5 In 85% of cancers, however,
telomerase activity is upregulated, counteracting the process
of telomere shortening and conferring unlimited proliferative
potential to malignant cells.6 As a result, therapeutic strategies
have been developed to inhibit telomerase function in
cancers.7
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One of the most promising therapeutic approaches is the use
of anti-hTR oligonucleotides that bind the RNA template and
thus act as catalytic inhibitors of telomerase.8−11 Therapeutic
efficacy has been demonstrated in various in vitro and in vivo
settings, and positive results have been reported for Imetelstat/
GRN163L in essential thrombocytopenia and myelofibro-
sis.12,13 Interestingly, several studies have shown that the use of
oligonucleotide template inhibitors causes cancer cell sensitiza-
tion to radiotherapy and chemotherapy as a result of telomere
length-dependent and telomere length-independent mecha-
nisms.14−20 To exploit this radiosensitizing effect, an
oligonucleotide hTR inhibitor was conjugated to indium-111
(111In) for concomitant telomerase inhibition and targeted
radionuclide therapy (TRT).21 111In emits Auger electrons that
cause dense ionizations over a short range (nm to μm), thus
allowing for irradiation of individual cells and sparing of non-
targeted tissue.22,23 This 111In-labeled hTR-targeted oligonu-
cleotide construct causes sequence- and telomerase-dependent
DNA damage and cell-killing effects in cancer cells.21 However,
the use of oligonucleotides as anticancer agents is hampered by
poor cellular uptake and unfavorable pharmacokinetics. There
is therefore an impetus in the field of DNA therapeutics to
devise new oligonucleotide delivery methods that can over-
come this barrier to the clinic.24
Nanosized drug carriers provide a platform for target-specific
delivery.25 In particular, gold nanoparticles (AuNPs) exploit
unique physicochemical properties that can augment intra-
cellular uptake of oligonucleotides. The AuNP surface can be
decorated with multiple moieties, allowing the design of
nanoparticles with a shell of targeting agents, cell-penetrating
peptides (CPPs), oligonucleotides, and other elements.25
AuNP−oligonucleotide constructs have been used for various
applications, including antisense gene control,26 gene ex-
pression knockdown with siRNA,27 intracellular detection of
RNA,28 and TRT.29−31 However, their potential as a vector for
hTR inhibition has not been explored, and the combination
with Auger electron radiotherapy has not been tested
previously.
Here, we describe the design, characterization, and in vitro
effect of a dual-modality therapeutic approach that uses 111In-
labeled anti-hTR oligonucleotide-functionalized AuNP con-
structs. Radiolabeled anti-hTR oligonucleotides were con-
jugated to 15.5 nm AuNPs to increase their cellular uptake and
resistance to endonuclease degradation. AuNPs were further
modified with attachment of polyethylene glycol (PEG) for
stability and Tat, a CPP/nuclear localization sequence (NLS),
for cellular and nuclear delivery.32−35 Detailed in vitro
characterization indicates that 111In-labeled anti-hTR oligonu-
cleotide- and Tat-functionalized AuNP constructs have a
telomerase-dependent cell-killing effect, thereby providing a
new avenue for the treatment of telomerase-positive cancers.
■ EXPERIMENTAL SECTION
Tissue Culture. The melanoma cell line MDA-MB-435 and
the osteosarcoma cell line U20S were used for cell studies. The
cell lines were obtained from the American Type Tissue
Culture Collection. The cells were kept in Dulbecco’s modified
Eagle’s medium (Sigma-Aldrich #D5796) with 10% fetal
bovine serum (Gibco #10270) and 1% penicillin/streptomy-
cin/glutamate (Sigma-Aldrich #G1146). The cells were
regularly passaged using 0.05% trypsin−EDTA (Gibson
#25300-054) and checked monthly for mycoplasma contam-
ination (MycoAlert testing kit; Lonza#LT07).
Gold Nanoparticles. AuNPs (15.5 nm) were synthesized
as described previously.26 The size and distribution of AuNPs
were determined by dynamic light scattering (DLS) with a
Zetasizer instrument (Malvern Instruments). The samples
were diluted to a concentration of 5 nM in Milli-Q water and
transferred to disposable plastic cuvettes at room temperature.
The samples were measured in triplicate, and the hydro-
dynamic radius was calculated using Stoke−Einstein’s relation
for the Brownian motion of particles. Particle size and
morphology were further analyzed using transmission electron
microscopy (TEM). The samples were lyophilized for 24 h on
TEM grids of 150 mesh (Agar Scientific AGG201N) and
images acquired using a Fei Tecnai 12 TE microscope and
imaged with a 16 megapixel Gatan OneView camera with
CMOS sensors. Images were obtained using a 1 s exposure
time and a pixel saturation of 5000−6000. Analysis was
performed using ImageJ software.
Fluorophore Labeling of Oligonucleotides. High-
performance liquid chromatography-purified 2′OMeRNA
with hTR complementary (Match) and random (Scramble)
oligonucleotide sequences with 5′-amino linkers and 3′-thiols
were purchased from Sigma-Aldrich. Oligonucleotides were
conjugated to Cy3-monoreactive dye (GE Healthcare
#PA23001) according to the manufacturer’s protocol. Using
P4 (BioRad #150-4120) size exclusion chromatography
(SEC), reaction products were separated into 50 μL
phosphate-buffered saline (PBS) fractions. The fractions
were analyzed by a spectrophotometer at wavelengths of 260
nm (oligonucleotides) and 550 nm (Cy3).
Radiolabeling of Oligonucleotides. Oligonucleotides
were dissolved in NaHCO3 buffer (0.1 M, pH 8.3) to a
concentration of 100 μM. Diethylenetriamine pentaacetate
(DTPA) (Sigma-Aldrich #284025-1G) was dissolved in
DMSO and added to the oligonucleotide solution in 10-fold
molar excess. The reaction was incubated for at least 120 min.
The reaction products were separated by SEC with P4-Biogel
into 50 μL of sodium citrate (0.1 M, pH 5.0; Sigma-Aldrich
#71498) fractions. The concentration was determined using a
spectrophotometer at a wavelength of 260 nm. Radiolabeling
was performed in sodium citrate (0.1 M, pH 5.0) by incubating
DTPA-labeled oligonucleotides with 111InCl3 (PerkinElmer
NEZ304A000MC) at a specific activity of 0.8 MBq/μg.
Radiolabeling efficiency was determined using a radio thin-
layer chromatography (TLC) imaging scanner (Bioscan #AR-
2000).
ON−AuNP Conjugates. ON−AuNP and ON−AuNP−
Tat conjugates were synthesized as described previously.26 For
ON−AuNPs, oligonucleotides (final concentration 3 μM)
were added to a 15 nM solution of 15.5 nm AuNPs. For ON−
AuNP−Tat, PEG800-SH (Sigma-Aldrich #729108) (final
concentration 45 μM) was dissolved in a 15 nM AuNP
solution for 20 min prior to the addition of oligonucleotides
(final concentration 1.5 μM). After a 10 min incubation with
oligonucleotides, Tat (sequence: GRKKRRQRRRPQGYGCG;
Cambridge Peptides; final concentration 1.5 μM) was added to
the solution. Both ON−AuNP and ON−AuNP−Tat were
subsequently incubated overnight. On day 2, Au-NP-
containing suspensions were salt-aged for 8 h to achieve a
final sodium chloride (NaCl; Sigma-Aldrich #S7653) concen-
tration of 0.3 M and then shaken overnight. The functionalized
AuNPs were purified by centrifugation (20,000g; 40 min; 4 °C,
three times) (Eppendorf #5417R), after which the pellet was
resuspended in Milli-Q water. New batches of AuNPs were
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prepared prior to each experiment, and the particle size and
morphology were determined as described above. The AuNP
constructs were reconstituted in sodium citrate (0.1 M, pH
5.0) prior to radiolabeling. Subsequently, 111InCl3 at the
desired specific activity was added and incubated overnight.
The next day, radiolabeling was confirmed with TLC, and
AuNPs were purified by centrifugation (20,000g; 40 min). The
number of oligonucleotides per particle was determined by
111In-labeling oligonucleotides with a known 111In/oligonu-
cleotide ratio prior to AuNP functionalization. ON−AuNP and
ON−AuNP−Tat were synthesized as described above, and
radiolabeled functionalized particles were centrifuged and
washed to remove unbound 111In. Subsequently, the
concentration of the pellet was measured with a spectropho-
tometer, and 111In counts per minute (CPM) in the pellet were
measured using a Wizard3” automatic gamma-counter
(PerkinElmer 2480). The number of oligonucleotides per
pellet was calculated by comparing the 111In CPM of the
resuspended pellet with a known standard of 111In CPM per
oligonucleotide. The stated concentration in an experiment
refers to the concentration of oligonucleotides conjugated to
the AuNP. The ON−AuNP concentration and quality were
determined by UV−vis spectrometry and DLS as described
above. A final ON concentration of 210 nM was determined in
clonogenic assays to exert the maximum effect and was used in
all other studies unless stated otherwise.
Telomeric Repeat Amplification Protocol. Cells were
harvested and lysed according to the TRAPeze XL Telomerase
Detection kit (EMD-Millipore #S7707) protocol. A known
concentration of inhibitor was added to the reaction mix, and
the polymerase chain reaction (PCR) protocol was started
with the following alterations: the first cycle was set to 30 °C
for 30 min, followed by 36 cycles at 94 °C for 30 s, 53.5 °C for
30 s, 72 °C for 60 s, and a final extension at 72 °C for 3 min.
After PCR, the samples were centrifuged (20,000g, 30 min, 4
°C) to remove AuNPs and measured using a plate reader.
Internalization and Fractionation Assays. For internal-
ization assays, the cells were incubated for 24 h, washed to
remove membrane-bound AuNPs using 0.1 M glycine HCl at
pH 2.5, and lysed with 0.1 M NaOH as previously described.36
A Nuclei EZ Prep Nuclei Isolation kit (Sigma-Aldrich
#NUC101-1KT) was used to determine the subcellular
distribution of AuNP constructs. The cytosol and nuclei
were isolated according to the manufacturer’s protocol. After
separation of fractions, the samples were counted in a
Wizard3” automatic gamma-counter.
Confocal Microscopy. The cells (2 × 105/well) were
seeded in eight-well chamber slides (Thermo Scientific
#177402), incubated overnight, and then treated with 210
nM Cy3−Match−AuNP or Cy3−Match−AuNP−Tat for 2.5
or 24 h in 200 μL media. The cells were then washed in PBS
before fixation in 200 μL of 4% formaldehyde (Sigma-Aldrich
#252549) for 10 min at room temperature. Before the removal
of the medium chamber from the slide, the cells were washed
three times with PBS. A drop of Vectashield (Vector #H-1200)
with 4′,6-diamidino-2-phenylindole (DAPI) was added to each
well, after which the samples were mounted using a 24 × 24
mm coverslip (VWR International #6310127). Images were
obtained using a laser scanning Leica microscope (TCS SP8).
Confocal planes were imaged using line-scanned consecutive
acquisition channels with a 63×/1.40 oil immersion lens (pixel
dwell time, 0.64 μs; pin-hole, 1 Airy unit).
Transmission Electron Microscopy. MDA-MB-435 cells
were plated onto Thermanox plastic coverslips (13 mm
diameter; Thermo Scientific, #174950) in six-well plates at a
seeding density of 8 × 105 cells and left to adhere overnight.
Fresh medium was added before incubation with 210 nM
Match−AuNP or Match−AuNP−Tat. After 24 h, the medium
was removed, and cells were washed twice in 1,4-
piperazinediethanesulfonic acid buffer (PIPES buffer; 0.1 M;
pH 7.2; Sigma-Aldrich # P8203) for 5 min. The samples were
prepared and stained as previously described.29 After staining,
the sections were analyzed on a Tecnai 12 TEM and imaged
with a 16 megapixel Gatan OneView camera with CMOS
sensors. Images were obtained using a 1 s exposure time, and a
pixel saturation of 5000−6000.
Clonogenic Assays. The cells were seeded in 96-well
plates at 2 × 104 cells/well overnight. The cells were incubated
with radiolabeled and non-radiolabeled free oligonucleotides,
ON−AuNP and ON−AuNP−Tat (27 MBq/nmol), for 24 h.
For radiosensitivity experiments, the cells were incubated with
AuNP constructs for 24 h and then exposed to external
ionizing radiation (IR) using a cesium-137 (137Cs)-irradiator
(0.662 MeV) to deliver a dose of 2, 4, or 6 Gy. After
incubation for 1 h, the cells were harvested following washing
in PBS and 50 μL of trypsin−EDTA was added. The harvested
cells were counted before plating in six-well plates at a density
sufficient to give more than 75 colonies per sample. The
untreated cells were typically seeded at 600 cells/well.
Colonies were grown for at least 7 days, washed in PBS, and
stained with 1% methylene blue (Alfa Aesar #A18174) in 50%
methanol (Fisher Scientific #M/4000/PC17). Excess stain was
washed off with water. Colonies containing more than 50 cells
were counted. The surviving fraction (SF) was calculated using
the plating efficiency of untreated cells. The mean inactivation
dose (MID), defined as MID = ∫ 0∞SF(D)dD, was calculated
for each curve following fitting of a linear-quadratic model.37,38
MIDs were compared using one-way ANOVA with Bonferroni
correction for multiple comparison. For radiosensitivity assays,
the sensitizer enhancement ratio (SER) was calculated by
dividing the MID of the non-AuNP-treated sample by the MID
of the AuNP-treated sample (SER = MIDNo AuNP/MIDAuNP).
γH2AX Assay. The cells (2 × 105/well) were seeded in an
eight-well chamber slide (Thermo Scientific #177402) and
incubated overnight. The cells were treated with 210 nM 111In-
labeled ON−AuNP−Tat (18 MBq/nmol) or medium for 24 h
in 200 μL medium. The positive control consisted of cells
exposed to external beam irradiation (4 Gy). After incubation,
the cells were washed twice in PBS, fixed in paraformaldehyde,
permeabilized with 1% Triton X-100 in PBS, and blocked for 1
h at 37 °C with 2% BSA in PBS.39 Fixed cells were incubated
with the anti-γH2AX primary antibody (JBW301; Millipore;
1:800 dilution) for 1 h at 37 °C, washed three times, and
exposed to AF488-labeled goat-anti-mouse antibody (Invi-
trogen; 1:250 dilution) for 1 h at 37 °C. The cells were washed
three times with PBS before removal of the medium chamber.
One drop of DAPI was added to each well, after which the
samples were mounted with a 24 × 24 mm coverslip (VWR
International #6310127). Images were obtained using a laser
scanning Leica confocal microscope (TCS SP8). Confocal
planes were imaged using line-scanned consecutive acquisition
channels through a 63×/1.40 oil immersion lens. The number
of γH2AX foci and nuclear surface area (NSA) were
automatically calculated using ImageJ software. All data is
expressed as foci/NSA.
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In Vivo Imaging and Biodistribution. 111In−Match−
AuNP−Tat or 111In−Scramble−AuNP−Tat (2.5 μg oligonu-
cleotide; 10 MBq) was administered intravenously (i.v.) to
female athymic nude mice bearing MDA-MB-435 xenografts
on the right flank (n = 3 per group). Single-photon emission
computerized tomography (SPECT) images were acquired 24,
48, and 72 h post-injection (p.i.) using the VECTor4CT
system (Milabs). Whole-body images were acquired over 30
min per mouse with an ultrahigh-resolution rat/mouse 1.8 mm
collimator (HE-UHR-RM) (6 timeframes, 30 s per bed
position, 10 positions). A CT scan (55 kV, 0.19 mA) was
performed for anatomical reference. SPECT images were
reconstructed using MiLabs ImageJ software. Animals were
euthanized after the 72 h p.i. imaging session, and organs were
removed and transferred to pre-weighed tubes. Tubes were
weighed again, and radioactivity was measured using a
Wizard3” automatic gamma-counter. Measurements were
decay-corrected to the activity at the time of injection. A
calibration curve was used to convert CPM to MBq, allowing
calculation of the percentage of injected dose per gram of
tissue (% ID/g).
■ RESULTS
Synthesis of hTR-Targeting AuNP Radiopharmaceu-
ticals. AuNPs were functionalized with either a monofunc-
tional layer of DTPA- or Cy3-tagged oligonucleotides (ON−
AuNP) or a multifunctional layer of DTPA- or Cy3-tagged
oligonucleotides plus PEG thiol (MW: 800; PEG800-SH) and
Tat peptide (ON−AuNP−Tat) (Figure 1A). AuNPs were
synthesized by citrate reduction of HAuCl4 as described
previously,40 resulting in the formation of spherical AuNP with
a mean diameter of 15.5 ± 1.9 nm and a hydrodynamic
diameter in Milli-Q water of 25.4 nm [polydispersity index
(PDI) 0.247] (Figure 1B,C,E). Match and Scramble sequence
oligonucleotides (Table 1) with 5′-end amino modification
were conjugated to the metal chelator DTPA using NHS/EDC
chemistry for labeling with 111In or with the fluorophore Cy3
for confocal microscopy. DTPA conjugation was confirmed by
radiolabeling with 111In, and Cy3-conjugation was assessed by
UV−vis spectrometry (Figure 1D and S1). Based on the
method by Rosi et al., AuNPs were functionalized with 3′-end
thiol-labeled oligonucleotides (ON−AuNP) by overnight
incubation, salt-aging, and purification.26 DLS analysis and
Figure 1. AuNP properties and functionalization. (A) Schematic of 111In−ON−AuNP and 111In−ON−AuNP−Tat. (B) Size distribution of 15.5 ±
1.9 nm AuNPs. (C) TEM image of AuNPs. (D) TLC reading of 111In−DTPA-labeled Match oligonucleotides. A peak at position = 25 mm,
revealing the presence of 111In−Match, covers the surface of 98% of the graph. A small amount of radioactivity is seen at approximately 75 mm,
indicating a trace amount of free 111In. (E) DLS of Match−AuNP and Scramble−AuNP in water. A rightward shift (from 25.4 to 33.3 nm) of
Match−AuNP and Scramble−AuNP indicates surface functionalization. (F) UV−vis spectrum of ON−AuNP in water. The overlapping of the
curves for AuNPs, Match−AuNP, and Scramble−AuNP suggests no aggregation, a rightward shift would indicate an increase in particle size. (G)
Typical TLC result for 111In−Match−AuNP and 111In−Scramble−AuNP (radiochemical purity 95 and 90%, respectively). (H) DLS of Match−
AuNP−Tat and Scramble−AuNP−Tat in water. A rightward shift from 25.4 to 38.4 nm (Match−AuNP−Tat) and 37.7 nm (Scramble−AuNP−
Tat) indicates surface functionalization. (I) UV−vis spectrum of ON−AuNP−Tat in water. The overlapping curves for AuNPs, Match−AuNP−
Tat, and Scramble−AuNP−Tat indicate particle stability with little or no aggregation. (J) Typical TLC for 111In−Match−AuNP−Tat and 111In−
Scramble−AuNP−Tat (radiochemical purity 98 and 99%, respectively).
Table 1. Oligonucleotide Sequences and Modifications
oligonucleotide sequence 5′−3′ modification 5′-end 3′-end
Match CAGUUAGGGUUAG 2′OMeRNA amine(AmC6) thiol
Scramble GCAGUGUGAUGAU 2′OMeRNA amine(AmC6) thiol
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UV−vis spectrophotometry demonstrated that functionalized
AuNPs did not aggregate and were monodisperse: the PDI of
Match−AuNP and Scramble−AuNP was 0.23 and 0.22,
respectively (Figure 1E,F). The hydrodynamic diameter of
the constructs increased from 25.4 nm for unmodified AuNPs
to 33.3 nm when decorated with either DTPA−Match
(hereafter referred to as Match) or DTPA−Scramble (here-
after referred to as Scramble) oligonucleotides, which is
consistent with an increase in size due to oligonucleotide
conjugation. Labeling of Match and Scramble with 111In prior
to AuNP functionalization allowed determination of the
average number of oligonucleotides per AuNP (Match−
AuNP, 76; Scramble−AuNP, 67), giving an oligonucleotide
radiolabeling efficiency of 33−38%. Several mixing strategies
and concentrations were tested for ON−AuNP−Tat synthesis.
Direct mixing of oligonucleotides and Tat with AuNPs resulted
in aggregation after salt-aging (data not shown). To minimize
this undesirable aggregation, hydrophilic PEG800-SH was
incorporated into the constructs. It was found that an AuNP/
PEG800-SH mixing ratio of 1:3000 was sufficient to avoid
aggregation when combined with AuNP/ON and AuNP/Tat
ratio of 1:100 after addition of 0.3 M NaCl. DLS demonstrated
Figure 2. Subcellular distribution of hTR-targeting AuNPs. (A) Internalization of ON−AuNP and ON−AuNP−Tat. * = significant difference
compared to free oligonucleotides (ON); † = significant difference compared to ON−AuNP (one-way ANOVA, multiple comparison, each
performed in three independent experiments). (B) Intracellular distribution (fractionation assays) of AuNPs, 111In−Match−AuNP, and 111In−
Match−AuNP−Tat. * = significant difference compared to 111InCl3; † = significant difference compared to 111In−Match−AuNP. * or †, p < 0.05;
** or ††, p < 0.01: *** or †††, p < 0.001; **** or ††††, p < 0.0001. Two-way ANOVA, multiple comparison, n = 3 replicates, four independent
experiments. (C) Subcellular distribution of AuNP constructs in MDA-MB-435 cells after incubation for 2.5 or 24 h. The cells were incubated with
medium only, Cy3−Match−AuNP (500 nM), or Cy3−Match−AuNP−Tat (500 nM). Images were acquired using a 63×/1.4 objective lens with
an additional 4× digital zoom. Nuclei were stained with DAPI. The scale bar is 10 μm. (D) Whole-cell TEM image of Match−AuNP-treated cells.
(D-1) Lysosome-like vesicle with Match−AuNP. (D-2) Endosomal vesicles with Match−AuNP. (E) Whole-cell image of Match−AuNP−Tat-
treated cells. (E-1) Large lysosomal vesicle with Match−AuNP−Tat. (E-2) Nucleus with Match−AuNP−Tat.
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that constructs were monodisperse in Milli-Q water with a PDI
value of 0.33 and 0.26 for Match−AuNP−Tat and Scramble−
AuNP−Tat, respectively (Figure 1H). UV−vis spectropho-
tometry indicated that there was no significant aggregation
(Figure 1I). The hydrodynamic diameter after functionaliza-
tion increased from 25.4 nm (AuNP) to 38.4 nm (Match−
AuNP−Tat) and 37.7 nm (Scramble−AuNP−Tat). The total
number of oligonucleotides per AuNP was 14 for Match−
AuNP−Tat and 16 for Scramble−AuNP−Tat, corresponding
to labeling efficiencies of 14 and 16% as determined by labeling
Match and Scramble with 111In prior to AuNP functionaliza-
tion. ON−AuNP and ON−AuNP−Tat were labeled with 111In
and purified by centrifugation prior to each experiment. The
maximum molar activity for ON−AuNP and ON−AuNP−Tat
was 27 and 18 MBq/nmol oligonucleotide, respectively. The
radiochemical purity after centrifugation was consistently
between 90 and 95% (Figure 1G,J).
Uptake and Trafficking of hTR-Targeting AuNP
Radiopharmaceuticals. To assess the cellular uptake of
AuNP constructs, a 24 h internalization assay was performed in
telomerase-positive MDA-MB-435 cells, and the uptake was
measured and calculated as a percentage of the total amount of
the added radioactivity (Figure 2A). The uptake of
oligonucleotides was markedly improved by linking them to
AuNPs: 111In−Match versus 111In−Match−AuNP, 0.30 ± 0.01
versus 3.62 ± 0.20% (p < 0.005); 111In−Scramble versus
111In−Scramble−AuNP, 0.26 ± 0.02 versus 4.17 ± 0.39% (p <
0.0001). The addition of Tat and PEG800-SH to the
nanocomplex further improved cellular internalization: 111In−
Match−AuNP versus 111In−Match−AuNP−Tat, 3.62 ± 0.20
versus 5.61 ± 0.969% (p = 0.0005); 111In−Scramble−AuNP
versus 111In−Scramble−AuNP−Tat, 4.17 ± 0.39 versus 5.67 ±
1.34% (p = 0.0095). To further investigate the subcellular
distribution of internalized AuNP constructs, fractionation
assays were performed in MDA-MB-435 cells (Figure 2B).
111In−Match−AuNP−Tat was taken up in the cytosol to a
significantly greater extent than 111In−Match−AuNP (4.88 ±
0.99 versus 2.13 ± 1.03%; p < 0.0001), and both were taken up
more than 111InCl3 (0.34 ± 0.15%; p < 0.0001 and p = 0.0024
for comparison to 111In−Match−AuNP−Tat and 111In−
Match−AuNP, respectively). The nuclear uptake of 111In−
Match−AuNP−Tat (1.65 ± 1.00%) was also significantly
greater than that of 111InCl3 (0.08 ± 0.044%, p = 0.0071).
However, the difference observed in the nuclear uptake of
111In−Match−AuNP−Tat and 111In−Match−AuNP was not
statistically significant (1.65 ± 1.00 versus 0.48 ± 0.17%, p =
0.06).
Cy3-labeled oligonucleotides were used to image AuNP
intracellular localization using confocal microscopy. MDA-MB-
435 cells were treated with medium only, Cy3−Match−AuNP
or Cy3−Match−AuNP−Tat for 2.5 or 24 h (Figure 2C). After
exposure to Cy3−Match−AuNP for 2.5 h, several intracellular
perinuclear Cy3 foci were observed, confirming cellular uptake.
A more intense Cy3 signal was seen for Match−AuNP−Tat, in
particular at the cell membrane with some foci of fluorescence
also observed in the perinuclear region. After incubation for 24
h, the Cy3 signal in Match−AuNP-treated cells was
predominantly localized to large cytoplasmic foci. Some
perinuclear foci were noted, but no nuclear fluorescence was
observed. In contrast, in Match−AuNP−Tat-treated cells,
there was a marked Cy3 signal in the perinuclear region at 2.5
h of treatment, and by 24 h, intranuclear foci were clearly
observed.
To investigate the subcellular distribution with greater
resolution, AuNPs were visualized in cells exposed for 24 h to
Match−AuNP and Match−AuNP−Tat using TEM (Figure
2D,E). Figure 2D shows a representative TEM image
demonstrating the subcellular distribution of Match−AuNP.
Black dots (AuNPs) were present in endosomal vesicles in the
cytosol, in agreement with the fluorescence images. Figure 2D-
1 shows a large lysosome-like vesicle that contains several
AuNPs. Figure 2D-2 highlights a smaller endosomal vesicle
with clustered AuNPs. No particles were observed in the
nucleus. In a representative image of a cell treated with
Match−AuNP−Tat (Figure 2E), most particles were located in
lysosomal vesicles in the perinuclear area (Figure 2E-1), but
individual particles were also observed in the nucleus (Figure
2E-2). The AuNPs predominantly appear as individual
particles, indicating that intracellular Match−AuNP and
Match−AuNP−Tat do not aggregate (Figure S3).
Telomerase Activity Inhibition by hTR-Targeting
AuNPs. The ability of AuNPs to inhibit telomerase activity
was measured with a gold standard cell-free PCR-based
technique, the telomeric repeat amplification protocol
(TRAP) assay (Figure S2A). Match, but not Scramble,
oligonucleotides inhibited telomerase in telomerase-expressing
MDA-MB-435 (log IC50 −6.93 ± 0.072) (Figure 3A),
consistent with previous results.21 The effect of ON−AuNPs
Figure 3. Telomerase activity inhibition by hTR-targeting AuNP constructs. (A) Dose effect of oligonucleotides on telomerase activity. The y-axis
represents the telomerase activity signal relative to the signal of untreated cells. The x-axis represents the logarithm of the concentration of
oligonucleotides (M). The plotted data points are the results for Match and Scramble. (B) Dose−response curve of ON−AuNP concentration
versus telomerase activity. (C) Dose−response curve of ON−AuNP−Tat concentration versus telomerase activity (n = 3 independent
experiments). (D) Effect of ON−AuNP−Tat on radiosensitivity. ON−AuNP−Tat (210 nM) was added to MDA-MB-435 cells for 24 h prior to
exposure to external IR and plated for clonogenic survival analysis. Curves were plotted using the linear-quadratic model. n = 4, three repeats per
experiment. Data points represent averages ± SEM.
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on telomerase activity was also tested using TRAP assays
(Figure 3B). Match−AuNP inhibited the telomerase activity in
a dose-dependent manner (log IC50 −7.49 ± 0.04, Hill slope
−1.46 ± 0.19). Scramble−AuNP did not significantly alter the
telomerase activity over the concentration range of 0.1−100
nm. Successful amplification of a pre-elongated primer, TSR8,
demonstrated that the construct did not inhibit the telomerase-
independent downstream steps of the TRAP assay (Figure
S2B).
TRAP assays were also conducted following exposure of
cells to ON−AuNP−Tat constructs (Figure 3C). Match−
AuNP−Tat inhibited the telomerase activity in a dose-
dependent manner (log IC50 −7.99 ± 0.05, Hill slope −1.05
± 0.27). Scramble−AuNP−Tat also demonstrated a dose-
dependent relationship (log IC50 −7.39 ± 0.03, Hill slope
−0.90 ± 0.06), although log IC50 was significantly higher than
for Match−AuNP−Tat (p < 0.0001). This result raised the
possibility that the Scramble−AuNP−Tat construct itself
interferes with the quantification technique, rather than
specifically inhibiting the telomerase activity. Consistent with
this, a significant reduction in the TRAP assay signal was
observed when the Tat-functionalized AuNP was added to
TSR8, indicating a telomerase-independent experimental
artifact (Figure S2C).
Match−AuNP−Tat Sensitizes Cells to External Beam
Radiation. Telomerase inhibition has been reported to
radiosensitize cells to IR,16,19,41 and AuNPs also demonstrate
this property.42 To investigate whether AuNPs and AuNP-
mediated delivery of hTR-inhibiting oligonucleotides were able
to sensitize cells to externally delivered IR, MDA-MB-435 cells
were treated with non-radiolabeled ON−AuNP−Tat (210
nM), exposed to external beam IR (0-6 Gy), and then
processed for clonogenic survival assays (Figure 3D). The
MID of Match−AuNP−Tat (2.02 ± 0.26) was significantly
lower than for the untreated (control) (3.23 ± 0.56, p = 0.022)
and Scramble−AuNP−Tat-treated samples (3.48 ± 0.66, p =
Figure 4. Radiobiological impact of radiolabeled hTR-targeting AuNPs. Clonogenic survival of MDA-MB-435 cells after treatment for 24 h with
(A) ON−AuNP, (B) ON−AuNP−Tat, and (C) 111InCl3, 111In−Scramble, and 111In−Match. (D) Clonogenic survival of U2OS after treatment for
24 h with 111In−ON−AuNP and 111In−ON−AuNP−Tat. In (A−D), curves were plotted using the linear quadratic model; n = 4−6, three
replicates per experiment. The y-axis represents the cell survival fraction. The x-axis represents the logarithm of the concentration of
oligonucleotides (M). Data points represent the mean ± SEM. γH2AX foci after treatment of (E) MDA-MB-435 and (F) U2OS cells with 111In−
ON−AuNP−Tat. Cells were treated with 111In−ON−AuNP−Tat (210 nM) or control for 24 h before fixation and staining for γH2AX. † =
significant difference compared to untreated control. * = significant difference compared to 111In−Scramble−AuNP−Tat. † or *, p < 0.05; †† or
**, p < 0.01: ††† or ***, p < 0.001; †††† or ****, p < 0.0001. Differences between samples were analyzed using one-way ANOVA, multiple
comparison (n = 65−125 cells).
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0.008). This resulted in an SER of 1.60 ± 0.12 for Match−
AuNP−Tat compared to an SER of 0.93 ± 0.06 for Scramble−
AuNP−Tat. The greater SER for match−AuNP−Tat is
attributed to its telomerase-inhibiting properties resulting in
radiosensitization.
hTR-Targeting AuNP Radiopharmaceuticals Reduce
Clonogenic Survival by Increasing Radiation-Induced
DNA Double-Strand Breaks. Since the ON−AuNP
constructs are designed to be deployed as radiopharmaceuti-
cals, the clonogenic survival of cells exposed to radiolabeled
ON−AuNP and ON−AuNP−Tat was evaluated using the
linear quadratic model in telomerase-positive MDA-MB-435
cells and telomerase-negative U2OS cells (Figure 4A−D).
111In-labeled ON−AuNP (Match and Scramble) constructs
had no significant impact on clonogenic survival of MDA-MB-
435 cells (Figure 4A) (p = 0.23). In contrast, 111In−Match−
AuNP−Tat significantly reduced clonogenic survival (SF at
210 nm 111In−Match−AuNP−Tat: 0.20 ± 0.11). 111In−
Match−AuNP−Tat showed a greater cell killing effect than
111In−Scramble−AuNP−Tat (MID: 0.11 ± 0.02 versus 0.15 ±
0.02, p = 0.03, one-way ANOVA, multiple comparison),
indicating a sequence-dependent effect of 111In−ON−AuNP−
Tat (Figure 4B). Furthermore, 111In−Match−AuNP−Tat had
a significant impact on clonogenic survival compared to non-
radiolabeled Tat-modified AuNP control: Match−AuNP−Tat
(p = 0.006), Scramble−AuNP−Tat (p = 0.002). 111In−
Scramble−AuNP−Tat showed a similar, although less
pronounced, difference compared to controls (p = 0.0237 for
Match−AuNP−Tat, p = 0.0037 for Scramble−AuNP−Tat).
Unconjugated 111InCl3,
111In-Match, and 111In-Scramble did
not significantly alter clonogenic survival (Figure 4C). A
control experiment in U2OS cells, which lack telomerase
activity, demonstrated a modest reduction in clonogenic
survival following treatment with 111In−Match−AuNP−Tat
and 111In−Scramble−AuNP−Tat at the highest concentration
(SF 0.73 ± 0.53 and 0.73 ± 0.37, respectively). This reduction
did not differ significantly from control treatments with
111InCl3,
111In−Match−AuNP, and 111In−Scramble−AuNP
(Figure 4D), indicating a modest telomerase-independent
effect.
To elucidate whether the observed radiotoxic effect of
AuNP- and Tat-mediated internalization of 111In is caused by
an increase in DNA damage, MDA-MB-435 and U2OS cells
were treated with radiolabeled AuNP constructs. Following
incubation for 24 h, the cells were exposed to the anti-γH2AX
antibody, as γH2AX is a well-validated marker of DNA double-
strand breaks (DSB).43 Cells exposed to 4 Gy external beam IR
were used as a positive control. Strong induction of γH2AX
was noted in MDA-MB-435 cells following 4 Gy of external
beam IR (foci/NSA was 0.12 ± 0.04 μm−2) (Figure 4E).
111In−Match−AuNP−Tat also caused a highly significant
upregulation of γH2AX foci/NSA in comparison to an
untreated control (0.12 ± 0.04 versus 0.07 ± 0.03 μm−2; p
< 0.0001) and to 111In−Scramble−AuNP−Tat (0.12 ± 0.04
versus 0.07 ± 0.03 μm−2; p < 0.0001). There was no difference
between untreated control and Scramble−AuNP−Tat. Fur-
thermore, the number of foci induced by 111In−Match−
AuNP−Tat was similar to that induced by IR (4 Gy)-treated
positive control cells (p = 0.303). The telomerase-dependency
of this effect was assessed using the telomerase-negative cell
line U20S (Figure 4F).
As with MDA-MB-435, robust induction of foci was
observed after treatment with 4 Gy IR compared to the
untreated control (p < 0.0001). 111In−Scramble−AuNP−Tat
caused a modest induction of γH2AX foci in U2OS cells as did
111In−Match−AuNP−Tat in this cell line. Both AuNP
constructs had a significantly higher number of foci/NSA
than the untreated control (111In−Scramble−AuNP−Tat: p =
0.0017; 111In−Match−AuNP−Tat: p = 0.0004) but did not
show a difference to each other (p = 0.9818). These results
indicate that the ability of 111In−Match−AuNPs to induce
DSBs is mediated by telomerase activity inhibition.
Biodistribution of 111In−ON−AuNP−Tat. A pilot study
of the in vivo biodistribution of 111In−Match−AuNP−Tat and
111In−Scramble−AuNP−Tat was performed in a murine
MDA-MB-435 xenograft model. Employing a combination of
SPECT imaging and ex vivo radioactivity quantification,
radiolabeled AuNPs demonstrated high liver and spleen
sequestration along with low tumor accumulation, 0.7% ID/g
(Figure S4).
■ DISCUSSION
Since the discovery of telomerase, strategies aiming to inhibit
this enzyme have been of great interest to the cancer research
community. Several studies have reported that optimal tumor
control has been achieved when telomerase inhibition is
combined with either external beam radiation or chemo-
therapy.20,44−46 It was therefore hypothesized that the
combination of telomerase inhibition plus radionuclide therapy
would be beneficial in the treatment of telomerase-positive
malignancies. This study is the first to report that 111In-labeled
anti-hTR oligonucleotide-functionalized AuNPs have a specific
anticancer therapeutic potential. Both the ON−AuNP and
ON−AuNP−Tat constructs delivered their payload into cells
with a roughly 10−20 times higher efficiency than free
oligonucleotides, strongly improving the uptake kinetics that
were reported previously.21 The extent of internalization of
AuNPs was comparable to previous reports by us and
others.30,47,48 Match−AuNP−Tat was internalized significantly
more than Match−AuNP, and there was a marked difference in
the fate of these two constructs after internalization. Match−
AuNP were concentrated in small foci around the cell
membrane and in the cytoplasm and were not observed
outside endosomal vesicles in TEM images, which is in
agreement with earlier research by Brandenberger et al. (2010)
who showed that AuNPs remained within vesicles in the
perinuclear space.49
The addition of PEG800-SH and Tat to the AuNP ligand
shell markedly enhanced the uptake kinetics of the particle.
The internalization of Cy3−Match−AuNP−Tat after 2.5 h
resulted in the formation of intense foci, indicating clustering
in endosomal vesicles, but a less intense uniform signal was
also noted in the cytosol and nucleus. This was more obvious
after 24 h, when high-density Cy3 focal spots were detected in
the perinuclear area and a more diffuse signal through the
cytosol and nucleus. This correlated with findings by TEM,
where AuNP dots were found in endosomal vesicles, as well as
in the nucleus and cytosol. A similar phenomenon was
observed by de la Fuente and Berry (2005), who used Tat for
the delivery of 2.4−8.2 nm AuNPs.32 Consistent with this,
Nativo et al. (2008) found that AuNPs loaded with PEG-SH,
Tat, and two other NLS exhibited perinuclear localization after
internalization.50 These investigators suggested that the
Molecular Pharmaceutics pubs.acs.org/molecularpharmaceutics Article
https://doi.org/10.1021/acs.molpharmaceut.1c00442
Mol. Pharmaceutics XXXX, XXX, XXX−XXX
H
accumulation of Tat-functionalized AuNPs in unusual
perinuclear membranous structures was the result of disruption
of endosomal membranes. Although perinuclear accumulation
was also detected in the current study, TEM revealed no
evidence of endosomal disruption. While a favorable intra-
cellular distribution of 111In-ON−AuNP-Tat was observed in
in vitro analyses, limited tumor accumulation in vivo was noted.
These findings are in agreement with a recent meta-analysis by
Wilhelm et al. and highlight the need for further optimization
of the delivery system through, for example, addition of a
tumor-specific ligand.51
In line with the data reported previously, it was shown that
telomerase activity can be inhibited by anti-hTR 2′OMeRNA
oligonucleotides in a concentration-dependent manner.21,52
Using the TRAP assay, addition of Match to AuNP resulted in
inhibition of telomerase activity (log IC50 −7.99 ± 0.05),
indicating that oligonucleotide conjugation to AuNP did not
hamper the anti-telomerase effect of Match. However,
although Scramble−AuNP did not exert an effect on
telomerase enzymatic activity, Scramble−AuNP−Tat did
induce dose-dependent telomerase inhibition (log IC50 −7.39
± 0.03). This apparently inconsistent result may be due to the
presence of Tat, which is highly positively charged and which
disrupted the PCR amplification stages of the TRAP assay. The
interference of this assay is a phenomenon that has been
reported in the literature53 and makes the result of the TRAP
assay hard to interpret in the presence of Tat. However, it is
interesting to point out that the inhibitory effect of Match−
AuNP−Tat is significantly higher than that of Scramble−
AuNP−Tat. This suggests that Match−AuNP−Tat may have a
specific effect on telomerase, which is detectable even when the
sensitivity of the assay is impaired due to the interference by
Tat.
Previously, researchers have demonstrated that hTR-binding
oligonucleotides can cause sensitization to external IR.14−20 To
investigate whether there was a telomerase-specific radio-
sensitizing effect when oligonucleotides were conjugated to
AuNPs, the cells were incubated with non-radiolabeled
Match−AuNP−Tat constructs and exposed to increasing
doses of externally delivered IR. The result of this experiment
showed a highly radiosensitizing effect with an SER for
Match−AuNP−Tat of 1.6, which is in line with the results
reported by Wu et al. (2017).19 These authors showed that
treatment with imetelstat prior to irradiation of Kyse410 and
Kyse520 cells led to SERs of 1.9 and 1.6, respectively.
However, although Wu et al. treated cells for 40 days prior to
irradiation, our results suggest that a 24 h treatment is
sufficient to elicit radiosensitization. This indicates that
telomere shortening is not the sole mechanism of action of
hTR inhibition-induced radiosensitization.
111In−Match−AuNP−Tat had a significant, dose-dependent
effect on the clonogenic survival of MDA-MB-435 cells. 111In−
Scramble−AuNP−Tat also led to a reduction in clonogenicity,
although this construct was significantly less effective. The
effect of the latter compound is likely the result of cellular
internalization of radiotoxic 111In.54 In this study, a correlation
is shown between the cytosolic and nuclear uptake of particles
and their capacity to reduce clonogenic survival of the
telomerase-positive cell line MDA-MB-435. Both Match−
AuNP and Match−AuNP−Tat inhibit the telomerase activity
in a cell-free system, but only 111In-labeled Match−AuNP−Tat
has a significant and telomerase-specific effect on clonogenic
survival. There is a discrepancy in the subcellular distribution
of both constructs, which is hypothesized to be the result of
the addition of Tat. For the constructs to inhibit hTR, they
must reach the nucleus. Furthermore, the effect of 111In is most
profound within a range of about 11 nm from DNA.55 Since
Match−AuNP−Tat is present in the nucleus in greater amount
than Match−AuNP, this may explain the greater reduction in
clonogenic survival with the Tat-modified construct. The
difference in effect between 111In−Match−AuNP−Tat and
111In−Scramble−AuNP−Tat can be explained by the differ-
ence in oligonucleotide sequence in the ligand shell of the two
constructs and is consistent with effective targeting of
telomerase by 111In−Match−AuNP−Tat but not 111In−
Scramble−AuNP−Tat. Crucially, there is no difference in
effect between these two constructs in cells that lack
telomerase expression (Figure 4F). Furthermore, these
constructs have a minimal effect on clonogenic survival when
not radiolabeled, which is keeping with previous findings.56−58
Chen et al. reported that a treatment time of 2 weeks with a
2′OMe anti-hTR oligonucleotide was enough to exert a
telomerase-specific radiosensitizing effect.56 Interestingly, this
time would be too short to induce critical telomere shortening,
implicating a non-canonical effect of hTR inhibition. This
correlates with the direct induction of DNA damage observed
in the current study which, it is proposed, is the underlying
cause of the reduction in clonogenic survival. Non-canonical
properties of hTR have been described and may account for
these observed effects. hTR has been shown to protect against
oxidative stress and apoptosis,59,60 as well as to stimulate DNA-
dependent kinase (DNA-PKcs) to phosphorylate hnRNPA1, a
protein critical for capping telomeres.61,62 Impairment of these
functions may result in increased DNA damage when
combined with radiation.
When taken together, the data showing sequence-specific
and radiolabel-dependent effects lead to the conclusion that
short-term hTR inhibition results in sensitization to the
radiotoxic effects of Auger electrons and external irradiation. In
agreement with this, we observed strong upregulation of
γH2AX foci after treatment with 111In−Match−AuNP−Tat
but not after treatment with 111In−Scramble−AuNP−Tat in
telomerase-positive cells. Furthermore, there was a modest
upregulation of γH2AX foci following exposure of telomerase-
negative cells to 111In−Match−AuNP−Tat and 111In−
Scramble−AuNP−Tat, but this was sequence-independent,
and likely the result of modest accumulation of intranuclear
111In. These results suggest that 111In−Match−AuNP−Tat
either causes more DNA damage than 111In−Scramble−
AuNP−Tat or inhibits the repair of such damage in
telomerase-positive cells. The results shown here are in line
with our previous work, which demonstrated that 111In-labeled
anti-hTR oligonucleotides have a telomerase-specific anti-
proliferative and cytotoxic effect via the induction of DNA
damage in three telomerase-positive cell lines.21 The current
study builds on this, demonstrating that AuNPs can function as
efficient cellular delivery vehicles for radiolabeled oligonucleo-
tides, eliminating the need for non-clinically relevant trans-
fectants.
■ CONCLUSIONS
In this paper, progress toward effective cellular delivery of
111In-labeled hTR-targeting oligonucleotides is reported. AuNP
constructs functionalized with a multivalent ligand shell of
PEG800-SH, Tat and 111In-labeled oligonucleotides exhibited
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a superior subcellular distribution profile in comparison to
AuNP constructs with a monovalent ligand shell of 111In-
labeled oligonucleotides only. Treatment with 111In−Match−
AuNP−Tat led to a sequence- and telomerase-dependent
DNA damage-induced reduction in clonogenic survival of
malignant cells, underlining its potential as a specific anticancer
agent. Overall, this work supports the concept that nucleic
acid-based anticancer radiopharmaceuticals represent a prom-
ising strategy for targeting tumors.
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